# Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

> **NCT01493882** · PHASE2 · WITHDRAWN · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.**

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-39758979 30 mg/d
- **DRUG:** JNJ-39758979 100 mg/d
- **DRUG:** JNJ-39758979 300 mg/d

## Key facts

- **NCT ID:** NCT01493882
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to 2 cases of agranulocytosis in a different clinical trial with this same drug.
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01493882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01493882, "Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01493882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*